What topics does this cannabis study cover?

This study covers research on: Addiction, Mental Health.

Cannabis cues trigger prefrontal GABA changes in use disorder

Q: What did this research study find?

The study used *magnetic resonance spectroscopy* during a cue-reactivity task to compare **22** people with *cannabis use disorder* with **19** matched non-cannabis-using controls.

Q: Where was this research published?

Published in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology on September 15, 2026.

Cue-elicited prefrontal gamma-aminobutyric acid (GABA) dynamics in cannabis use disorder.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology • September 15, 2026 • Highly Relevant

🤖

AI Summary

This human study asked whether cannabis-related cues produce different changes in gamma-aminobutyric acid (GABA) and Glx—a measure of glutamate and glutamine—in the dorsolateral prefrontal cortex (dlPFC) of people with cannabis use disorder. Researchers used magnetic resonance spectroscopy during a cue-reactivity task in 22 people with cannabis use disorder, including 11 females, and compared them with 19 matched non-cannabis-using controls, including 9 females.

Overall resting or task-period GABA+ levels were similar between groups, but the groups responded differently to the cues. Participants with cannabis use disorder showed increased GABA+ during cannabis-cue exposure compared with neutral cues, regardless of which cue type was presented first; the abstract does not report a corresponding significant Glx finding. The study suggests that cue-based MRS may reveal neurometabolic changes not visible under general conditions and may help investigate candidate biomarkers. However, this abstract-based summary cannot establish that the GABA response causes craving or relapse, or that changing it would improve treatment outcomes.

💡 Key Findings

The study used magnetic resonance spectroscopy during a cue-reactivity task to compare 22 people with cannabis use disorder with 19 matched non-cannabis-using controls.

High

90%

Although overall GABA+ levels were similar between groups, participants with cannabis use disorder showed increased GABA+ during cannabis cues versus neutral cues.

High

85%

The cue-related GABA response differed between groups regardless of cue presentation order, suggesting that cue exposure may reveal changes not apparent under general conditions.

High

80%

The findings support cue-elicited GABA dynamics as a candidate biomarker for studying cannabis use disorder, but they do not establish a treatment benefit or causal role in relapse.

Good

75%

📄 Original Abstract

Chronic cannabis use drives neuroadaptations in reward and stress-related circuits that condition the brain to the drug and its associated cues. These changes underlie craving and heighten its sensitivity to cue- and stress-induced triggers, sustaining drug intake and promoting relapse. Task-based functional magnetic resonance imaging of drug cue reactivity paradigms has shown the dorsolateral prefrontal cortex (dlPFC) as one region commonly activated during cue-elicited craving. However, the state-induced dynamics of critical neurometabolites in cannabis use disorder remain to be investigated. The present study addresses this gap by investigating gamma-aminobutyric acid (GABA) and Glx (glutamate and glutamine) in the dlPFC during cannabis cue reactivity in individuals with cannabis use disorder (n = 22; 11 females) compared to matched non-cannabis using controls (n = 19; 9 females). Magnetic resonance spectroscopy (HERMES) data were acquired from the dlPFC during a cue reactivity paradigm and analyzed using GANNET. We found that, while individuals with cannabis use disorder and controls had similar overall GABA+ levels, they responded differently to cue reactivity, where individuals with cannabis use disorder showed increases in GABA+ during cannabis cue reactivity compared to neutral cue reactivity, irrespective of presentation order (F1,16 = 7.31, p = 0.016, n2p = .31). These findings indicate that cannabis cue reactivity may reveal neurometabolic alterations that are not observable under rest conditions. These findings also establish MRS cue-reactivity paradigms as a valuable tool for probing the neurobiology of cannabis use disorder and identify cue-elicited GABA dynamics as a clinically relevant biomarker amenable to therapeutic intervention.

Paper Type

📄 Research

Publication

Journal: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
Published: September 15, 2026
PMID: 42745011
DOI: 10.1038/s41386-026-02563-3

Authors (5)

Alexandra Gaillard School of Health Sciences, Department of Biomedical, Health & Exercise Sciences, Swinburne University of Technology, Melbourne, Australia. agaillard@swin.edu.au.
Daniel J Fehring School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.
Philip J Sumner School of Health Sciences, Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Melbourne, Australia.
Alisha Randhawa School of Health Sciences, Department of Biomedical, Health & Exercise Sciences, Swinburne University of Technology, Melbourne, Australia.
Susan L Rossell School of Health Sciences, Department of Biomedical, Health & Exercise Sciences, Swinburne University of Technology, Melbourne, Australia.